Jiangsu Recbio Technology Co., Ltd. (2179.HK)
- Previous Close
9.040 - Open
9.290 - Bid 8.640 x --
- Ask 9.100 x --
- Day's Range
8.800 - 9.290 - 52 Week Range
6.760 - 9.970 - Volume
6,000 - Avg. Volume
90,921 - Market Cap (intraday)
4.376B - Beta (5Y Monthly) -0.26
- PE Ratio (TTM)
-- - EPS (TTM)
-1.260 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China. The company is developing vaccines for the treatment of cervical cancer, and anal and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601 and REC602 recombinant HPV bivalent vaccines targeting HPV type 6/11, which are in phase I clinical trials; REC604a, a recombinant HPV quadrivalent vaccine that is in pre-clinical stage; and REC604b, a recombinant HPV 9-valent vaccine that is in pre-clinical stage. It also develops ReCOV, a recombinant COVID-19 vaccine candidate that is in Phase II/III trial; REC610, a recombinant shingles vaccine that is in Phase l clinical trial; and REC617, a recombinant influenza quadrivalent vaccine that is in pre-clinical stage. Jiangsu Recbio Technology Co., Ltd. was founded in 2012 and is headquartered in Taizhou, the People's Republic of China.
www.recbio.cnRecent News: 2179.HK
View MorePerformance Overview: 2179.HK
Trailing total returns as of 5/21/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2179.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2179.HK
View MoreValuation Measures
Market Cap
4.37B
Enterprise Value
4.84B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
7.61
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-17.32%
Return on Equity (ttm)
-70.23%
Revenue (ttm)
27M
Net Income Avi to Common (ttm)
-557.46M
Diluted EPS (ttm)
-1.260
Balance Sheet and Cash Flow
Total Cash (mrq)
450.35M
Total Debt/Equity (mrq)
167.97%
Levered Free Cash Flow (ttm)
-390.32M